for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

HUTCHMED (China) Ltd

HCM.L

Latest Trade

538.00GBp

Change

-9.00(-1.65%)

Volume

58,878

Today's Range

532.00

 - 

551.00

52 Week Range

337.00

 - 

656.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Hutchmed (China) Says NMPA Granted Breakthrough Therapy Designation To Amdizalisib

Sept 13 (Reuters) - HUTCHMED (China) Ltd <0013.HK>::NMPA GRANTED BREAKTHROUGH THERAPY DESIGNATION TO AMDIZALISIB (HMPL-689).GRANTED BREAKTHROUGH THERAPY DESIGNATION TO AMDIZALISIB (HMPL-689) FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.Further company coverage: 0013.HK. ((Reuters.Briefs@thomsonreuters.com;)).

Hutchmed (China) Says Co And Astrazeneca Initiate Phase II Trial Of Orpathys

July 28 (Reuters) - HUTCHMED (China) Ltd <0013.HK>::CO AND ASTRAZENECA INITIATE PHASE II TRIAL OF ORPATHYS IN PATIENTS WITH MET AMPLIFIED GASTRIC CANCER.Further company coverage: 0013.HK. ((Reuters.Briefs@thomsonreuters.com;)).

Capital Group Companies Inc's Long Position In HUTCHMED Rises To 9.15% - HKEX Filing

July 16 (Reuters) - Hong Kong stock exchange filing::THE CAPITAL GROUP COMPANIES INC'S LONG POSITION IN HUTCHMED <<<0013.HK>>> INCREASED TO 9.15% ON JULY 9 FROM 8.95% - HKEX FILING.

Hutchmed (China) Marketing Authorization Application for Surufatinib Validated by EMA

July 16 (Reuters) - HUTCHMED (China) Ltd <0013.HK>::EUROPEAN MEDICINES AGENCY VALIDATED AND ACCEPTED ITS MARKETING AUTHORIZATION APPLICATION FOR SURUFATINIB.

The Capital Group Companies Inc Raises Stake In HUTCHMED To 8.3% - HKEX Filing

July 15 (Reuters) - Hong Kong stock exchange filing::THE CAPITAL GROUP COMPANIES INC BOUGHT 13.95 MLN SHARES IN HUTCHMED <<<0013.HK>>> AT AVG PRICE OF HK$55.42 ($7.13) PER SHARE ON JUNE 30 - HKEX FILING.THE CAPITAL GROUP COMPANIES INC'S LONG POSITION IN HUTCHMED RISES TO 8.30% FROM 8.18% - HKEX FILING.

JPMorgan Chase & Co's Long Position In Hutchmed Rises To 5.14% On June 30 - HKEX Filing

July 13 (Reuters) - Hong Kong stock exchange filing::JPMORGAN CHASE & CO'S LONG POSITION IN HUTCHMED <<<0013.HK>>> INCREASED TO 5.14% ON JUNE 30 FROM 0.0% - HKEX FILING.

U.S. FDA Accepts Filing Of Hutchmed’S NDA For Surufatinib For The Treatment Of Advanced Neuroendocrine Tumors

July 1 (Reuters) - HUTCHMED (China) Ltd <0013.HK>::U.S. FDA ACCEPTS FILING OF HUTCHMED’S NDA FOR SURUFATINIB FOR THE TREATMENT OF ADVANCED NEUROENDOCRINE TUMORS.HUTCHMED (CHINA) LTD - PDUFA GOAL DATE ASSIGNED BY FDA FOR THIS NDA IS APRIL 30, 2022.

Hutchmed says evaluating possibility of seeking listing in Shanghai's Science And Technology Innovation Board

June 30 (Reuters) - HUTCHMED (China) Ltd <0013.HK>::SAYS EVALUATING POSSIBILITY OF SEEKING LISTING IN SHANGHAI STOCK EXCHANGE SCIENCE AND TECHNOLOGY INNOVATION BOARD.

Hutchmed China Announces Pricing Of Global Offering

June 23 (Reuters) - HUTCHMED (China) Ltd <HCM.L>::HUTCHMED CHINA LTD - HUTCHMED ANNOUNCES PRICING OF GLOBAL OFFERING.HUTCHMED (CHINA) LTD - FINAL OFFER PRICE FOR BOTH INTERNATIONAL OFFERING AND HONG KONG PUBLIC OFFERING HAS BEEN SET AT HK$40.10 PER SHARE.

HUTCHMED (China) Announces Launch Of Its Hong Kong Public Offering

June 18 (Reuters) - HUTCHMED (China) Ltd <HCM.L>::HUTCHMED CHINA LTD - HUTCHMED LAUNCHES HONG KONG IPO.HUTCHMED (CHINA) LTD - LAUNCH OF ITS HONG KONG PUBLIC OFFERING.HUTCHMED (CHINA) LTD - WILL RECEIVE ALL OF NET PROCEEDS FROM GLOBAL OFFERING.HUTCHMED (CHINA) LTD - LAUNCH OF ITS HONG KONG PUBLIC OFFERING WHICH FORMS PART OF GLOBAL OFFERING OF 104 MILLION NEW ORDINARY SHARES.HUTCHMED (CHINA) - OFFERING INITIALLY COMPRISES 13 MILLION NEW SHARES UNDER HK OFFERING AND 91 MILLION NEW SHARES UNDER INTEREST'L OFFERING.HUTCHMED (CHINA) LTD - OFFER PRICE FOR GLOBAL OFFERING WILL BE NOT MORE THAN HK$45.00 PER SHARE.HUTCHMED (CHINA) - ENTERED INTO CORNERSTONE INVESTMENT DEALS WITH CARLYLE, CPPIB, GENERAL ATLANTIC, HBM HEALTHCARE INVESTMENTS AND CICC GRANDEUR FUND.HUTCHMED (CHINA) LTD - CORNERSTONE INVESTMENT ENTITIES AGREED TO SUBSCRIBE FOR SHARES WORTH $325 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up